Compare Summit Therapeutics Inc (SMMT) vs Teucrium Wheat Fund (WEAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Teucrium Wheat Fund — how do they compare? Summit Therapeutics Inc trades at $17.59 (market cap $13.71B), while Teucrium Wheat Fund trades at $24.41 (market cap $273.67M). The key difference: Summit Therapeutics Inc is far larger — about 50.1× Teucrium Wheat Fund's market cap, and Teucrium Wheat Fund is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Teucrium Wheat Fund for 40 Days on average.
| SMMT | WEAT | |
|---|---|---|
Market Cap | $13.71B | $273.67M |
Volume | 6,173,057 | 222,576 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $26.38 | $28.00 |
52-Week Low | $12.43 | $19.88 |
Typical Hold Time | 16 Days | 40 Days |
Enterprise Value | $13.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.
The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.
WEAT is trading at $24.41, down 1.97% with a bearish technical outlook as moving averages signal selling pressure. The wheat ETF faces mixed sentiment with recent price gains of 9.9% over the past month but current technical indicators showing weakness. Key support sits at $24 with resistance at $25, creating a tight trading range.
The ETF's performance remains tied to agricultural commodity volatility and inflation trends. Recent inflation data shows prices above Fed targets, potentially supporting commodity investments. However, technical weakness and the question of whether the recent rally is overdone present near-term challenges for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Teucrium Wheat Fund
WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →
